These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 27564658)

  • 1. Decreased circulating thrombomodulin is improved by tadalafil therapy in hypoxemic patients with advanced pulmonary arterial hypertension.
    Maeda NY; Clavé MM; Bydlowski SP; Lopes AA
    Thromb Res; 2016 Oct; 146():15-19. PubMed ID: 27564658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphodiesterase type 5 inhibitors improve microvascular dysfunction markers in pulmonary arterial hypertension associated with congenital heart disease.
    Clavé MM; Maeda NY; Thomaz AM; Bydlowski SP; Lopes AA
    Congenit Heart Dis; 2019 Mar; 14(2):246-255. PubMed ID: 30343508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study.
    Oudiz RJ; Brundage BH; Galiè N; Ghofrani HA; Simonneau G; Botros FT; Chan M; Beardsworth A; Barst RJ;
    J Am Coll Cardiol; 2012 Aug; 60(8):768-74. PubMed ID: 22818063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in gene expression profiles in patients with pulmonary arterial hypertension associated with scleroderma treated with tadalafil.
    Cheong FY; Gower AC; Farber HW
    Semin Arthritis Rheum; 2017 Feb; 46(4):465-472. PubMed ID: 27499522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tadalafil in idiopathic or heritable pulmonary arterial hypertension (PAH) compared to PAH associated with connective tissue disease.
    Galiè N; Denton CP; Dardi F; Manes A; Mazzanti G; Li B; Varanese L; Esler A; Harmon C; Palazzini M
    Int J Cardiol; 2017 May; 235():67-72. PubMed ID: 28279499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension.
    Hassoun PM; Zamanian RT; Damico R; Lechtzin N; Khair R; Kolb TM; Tedford RJ; Hulme OL; Housten T; Pisanello C; Sato T; Pullins EH; Corona-Villalobos CP; Zimmerman SL; Gashouta MA; Minai OA; Torres F; Girgis RE; Chin K; Mathai SC
    Am J Respir Crit Care Med; 2015 Nov; 192(9):1102-10. PubMed ID: 26360334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initial tadalafil and ambrisentan combination therapy in pulmonary arterial hypertension: cLinical and haemodYnamic long-term efficacy (ITALY study).
    D'Alto M; Romeo E; Argiento P; Paciocco G; Prediletto R; Ghio S; Correale M; Lo Giudice F; Badagliacca R; Greco A; Vizza CD
    J Cardiovasc Med (Hagerstown); 2018 Jan; 19(1):12-17. PubMed ID: 29215546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effects of iloprost combined with low dose tadalafil in adult congenital heart disease patients with severe pulmonary arterial hypertension: a single-center, open-label controlled study].
    Zhang C; Huang Y; Huang T; Xia C; Huang X; Zhang G; Yao H; Chen J; Chen J; Wu S; Zhuang J
    Zhonghua Xin Xue Guan Bing Za Zhi; 2014 Jun; 42(6):474-80. PubMed ID: 25164220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of PDE-5 inhibitor tadalafil in pulmonary arterial hypertension.
    Bharani A; Patel A; Saraf J; Jain A; Mehrotra S; Lunia B
    Indian Heart J; 2007; 59(4):323-8. PubMed ID: 19126937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study.
    Kimura M; Tamura Y; Takei M; Yamamoto T; Ono T; Fujita J; Kataoka M; Kuwana M; Satoh T; Fukuda K
    BMC Pulm Med; 2015 May; 15():62. PubMed ID: 25971443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conversion from sildenafil to tadalafil: results from the sildenafil to tadalafil in pulmonary arterial hypertension (SITAR) study.
    Frantz RP; Durst L; Burger CD; Oudiz RJ; Bourge RC; Franco V; Waxman AB; McDevitt S; Walker S
    J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):550-7. PubMed ID: 24742768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tadalafil: a long-acting phosphodiesterase-5 inhibitor for the treatment of pulmonary arterial hypertension.
    Arif SA; Poon H
    Clin Ther; 2011 Aug; 33(8):993-1004. PubMed ID: 21762988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study.
    Ghofrani HA; Voswinckel R; Reichenberger F; Olschewski H; Haredza P; Karadaş B; Schermuly RT; Weissmann N; Seeger W; Grimminger F
    J Am Coll Cardiol; 2004 Oct; 44(7):1488-96. PubMed ID: 15464333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy with prostacyclin and tadalafil for severe pulmonary arterial hypertension: a pilot study.
    Bendayan D; Shitrit D; Kramer MR
    Respirology; 2008 Nov; 13(6):916-8. PubMed ID: 18811891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral Tadalafil in Children with Pulmonary Arterial Hypertension.
    Shiva A; Shiran M; Rafati M; Zamani H; Babazadeh K; Saeedi M; Ala S
    Drug Res (Stuttg); 2016 Jan; 66(1):7-10. PubMed ID: 25611962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension.
    Falk JA; Philip KJ; Schwarz ER
    Vasc Health Risk Manag; 2010 May; 6():273-80. PubMed ID: 20479949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathic pulmonary arterial hypertension.
    Diller GP; van Eijl S; Okonko DO; Howard LS; Ali O; Thum T; Wort SJ; Bédard E; Gibbs JS; Bauersachs J; Hobbs AJ; Wilkins MR; Gatzoulis MA; Wharton J
    Circulation; 2008 Jun; 117(23):3020-30. PubMed ID: 18519847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tadalafil for the treatment of pulmonary arterial hypertension.
    Frey MK; Lang I
    Expert Opin Pharmacother; 2012 Apr; 13(5):747-55. PubMed ID: 22356534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Age on Phenotype and Outcomes in Pulmonary Arterial Hypertension Trials.
    Rose JA; Cleveland JM; Rao Y; Minai OA; Tonelli AR
    Chest; 2016 May; 149(5):1234-44. PubMed ID: 26836910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tadalafil for the treatment of pulmonary arterial hypertension.
    Rosenzweig EB
    Expert Opin Pharmacother; 2010 Jan; 11(1):127-32. PubMed ID: 20001434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.